Physician profile
Beatriz Mayor
$1,550.10
in general payments reported to CMS, 2019-2025
11 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $875 · 2023: $97.00 · 2024: $357 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $337.90 | 2024-2025 | Breztri, Airsupra |
| Alexion Pharmaceuticals, INC. | $249.86 | 2022 | |
| Amneal Pharmaceuticals LLC | $241.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $175.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.58 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $115.96 | 2025 | Rexulti |
| Aprecia Pharmaceuticals, LLC | $98.38 | 2022 | |
| Biogen, INC. | $97.00 | 2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $71.59 | 2022 | |
| Kyowa Kirin, INC. | $24.00 | 2022 | |
| Eisai INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Mayor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.